Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINE-START
2025-523075-32-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone with Placebo (2 arms). Primary endpoint: Change in UACR from baseline over 6 months. Planned start Dec 2025; status: authorised.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2025-523075-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523075-32-00.